Study Of Sunitinib With S-1 And Cisplatin For Gastric Cancer

Pfizer

Status and phase: Completed; Phase 1

Conditions: Stomach Neoplasms

Treatments: Drug: Sunitinib; Drug: Cisplatin; Drug: S-1

Study type: Interventional

Funder types: Industry

Identifiers

NCT00553696

A6181127

Details and patient eligibility

About

To assess the maximal tolerated dose (MTD) and overall safety of sunitinib when administered in combination with S-1 and Cisplatin in patients with advanced/metastatic gastric cancer.

Enrollment: 27 patients

Sex: All

Ages: 20+ years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Histologically or cytologically confirmed diagnosis of gastric cancer
• Chemonaive patients
• Adequate organ function

Exclusion criteria

• Patients who meet the contra-indications of S-1 and Cisplatin.
• Prior chemotherapy failure patients

Trial design

Primary purpose: Treatment

Allocation: N/A

Interventional model: Single Group Assignment

Masking: None (Open label)

---

27 participants in 1 patient group

A

Experimental group

Treatment:

Drug: Cisplatin

Drug: S-1

Drug: Sunitinib